临床儿科杂志 ›› 2021, Vol. 39 ›› Issue (11): 860-.doi: 10.3969/j.issn.1000-3606.2021.11.016

• 综合报道 • 上一篇    下一篇

儿童门冬酰胺酶相关性胰腺炎21 例临床分析

张智晓, 陆爱东, 左英熹, 贾月萍, 丁明明, 张乐萍   

  1. 北京大学人民医院儿科(北京 100044)
  • 发布日期:2021-11-19
  • 通讯作者: 张乐萍 电子信箱:zhangleping 2021 @163 .com
  • 基金资助:
    2018年度北京市临床重点专科建设项目-儿科(No. 2199000726)

Clinical analysis of 21 cases of childhood asparaginase-associated pancreatitis

ZHANG Zhixiao, LU Aidong, ZUO Yingxi, JIA Yueping, DING Mingming, ZHANG Leping   

  1. Department of Pediatrics, Peking University People’s Hospital, Beijing 100044 , China
  • Published:2021-11-19

摘要: 目的 总结儿童门冬酰胺酶(Asp)相关性胰腺炎(AAP)的临床特征及预后。方法 纳入2012年1月至2019 年12月初诊并接受Asp联合化疗后出现急性胰腺炎的21例急性淋巴细胞白血病(ALL)患儿,分析其临床特征、实验室检 查、治疗情况和预后。结果 研究期间初诊并接受Asp治疗的ALL患儿共711例,21例患儿发生AAP,发生率为3.0%。21 例患儿中,男10例、女11例,中位年龄8岁(3~18岁);7例AAP发生于诱导化疗期,L-asp中位次数7次(1~10次);14例 发生于巩固化疗期,PEG-asp治疗后16 . 5天(2 ~ 22天),中位次数4.5次(1~9次)。轻型AAP 14例,重型7例;腹痛、呕吐 为最常见的症状。AAP诊断时,血清淀粉酶和脂肪酶中位数分别为471 U/L(范围25~1632 U/L)和287.1 U/L(范围4.6~2213.7 U/L)。13例患儿行腹部超声,6例(46.2%)阳性;20例行腹部CT,17例(85.0%)阳性。4例AAP患儿出现胰腺假性囊肿。 所有患儿均在早期予禁食、抑酸、抑制胰酶分泌、营养支持等治疗,3例采用经鼻空肠管喂养,5例行手术干预。4例轻型 AAP患儿再次使用L-asp化疗,其中1例再发AAP。末次随访时,除1例患儿放弃治疗外,无胰腺炎相关死亡病例,1例发 生慢性胰腺炎,其余19例胰腺炎已愈。结论 AAP是Asp治疗过程中的严重并发症,早期识别是关键,总体预后良好。

关键词: 门冬酰胺酶; 门冬酰胺酶相关性胰腺炎; 急性淋巴细胞白血病; 儿童

Abstract: Objective To analyze clinical characteristics, diagnosis, treatment and prognosis of asparaginase-associated pancreatitis (AAP) in children. Methods From January 2012 to December 2019 , 21 children with acute pancreatitis who were newly diagnosed with acute lymphoblastic leukemia (ALL) and received asparaginase-containing chemotherapy were included. Their clinical characteristics, laboratory examinations, treatment and prognosis were retrospectively analyzed. Results Among the 711 children newly diagnosed with ALL and treated with L-asparaginase (L-asp) during the study period, the incidence of AAP was 3 . 0 % (n= 21 ). Among the 21 cases, there were 10 boys and 11 girls, with a median age of 8 years (range: 3 ~ 18 years). Seven cases occurred during induction chemotherapy, after a median L-asp doses of 7 (range:1 ~ 10 doses), and 14 cases occurred in consolidation chemotherapy, with a median interval of 16 . 5 days (range:2 ~ 22 days) after PEG-asp administration, and the median number of PEG-asp doses was 4 . 5 (range:1 ~ 9 doses). Fourteen cases were classified as mild and 7 were severe. Abdominal pain and vomiting were the most common symptoms. The median values of serum amylase and lipase at AAP diagnosis were 471 U/L (range: 25 ~ 1632 U/L, upper normal limit [UNL]: 125 U/L) and 287 . 1 U/L (range: 4 . 6 ~ 2213 . 7 U/L, UNL: 31 U/L) respectively. Thirteen children underwent abdominal ultrasound examination, 6 ( 46 . 2 %) were positive; 20 cases underwent abdominal CT scan, 17 ( 85 . 0 %) were positive. Pancreatic pseudocyst occurred in 4 cases. All children received conservative management including fasting, administration of somatostatin or acid suppression drugs and nutrition support. Three cases received nasojejunal feeding, and 5 cases required surgery. Four cases with mild AAP were re-exposed to L-asp, of which one case had recurrent AAP. Except for one child who gave up treatment, there were no pancreatitis-related deaths. One case developed chronic pancreatitis and the other 19 cases were cured. Conclusion AAP is a serious complication of asparaginase therapy. Early identification is of utmost importance. The prognosis is good with multidisciplinary comprehensive treatment.

Key words: asparaginase; asparaginase-associated pancreatitis; acute lymphoblastic leukemia; child